In the Alzheimer’s disease brain, the amyloid beta peptide clumps together to form hardened plaques between nerve cells.
Key Takeaways
- Researchers have developed a method based on artificial intelligence that rapidly identifies currently available medications that may treat Alzheimer’s disease.
- The method also reveals potential new treatment targets for the disease.
Independent validation of the nominated drug targets could provide new insights into the mechanisms behind Alzheimer’s disease and lead to novel therapies.
Mark Albers, MD, PhD
Associate Director, Massachusetts Center for Alzheimer Therapeutic Science, Massachusetts General Hospital
New treatments for Alzheimer’s disease are desperately needed, but numerous clinical trials of investigational drugs have failed to generate promising options. Now a team at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) has developed an artificial intelligence–based method to screen currently available medications as possible treatments for Alzheimer’s disease. The method could represent a rapid and inexpensive way to repurpose existing therapies into new treatments for this progressive, debilitating neurodegenerative condition. Importantly, it could also help reveal new, unexplored targets for therapy by pointing to mechanisms of drug action.
“Repurposing FDA-approved drugs for Alzheimer’s disease is an attractive idea that can help accelerate the arrival of effective treatment—but unfortunately, even for previously approved drugs, clinical trials require substantial resources, making it impossible to evaluate every drug in patients with Alzheimer’s disease,” explains Artem Sokolov, PhD, director of Informatics and Modeling at the Laboratory of Systems Pharmacology at HMS. “We therefore built a framework for prioritizing drugs, helping clinical studies to focus on the most promising ones.”
In an article published in Nature Communications, Sokolov and his colleagues describe their framework, called DRIAD (Drug Repurposing In Alzheimer’s Disease), which relies on machine learning—a branch of artificial intelligence in which systems are “trained” on vast amounts of data, “learn” to identify telltale patterns and augment researchers’ and clinicians’ decision-making.
DRIAD works by measuring what happens to human brain neural cells when treated with a drug. The method then determines whether the changes induced by a drug correlate with molecular markers of disease severity.
The approach also allowed the researchers to identify drugs that had protective as well as damaging effects on brain cells.
“We also approximate the directionality of such correlations, helping to identify and filter out neurotoxic drugs that accelerate neuronal death instead of preventing it,” says co-first author Steve Rodriguez, PhD, an investigator in the Department of Neurology at MGH and an instructor at HMS.
DRIAD also allows researchers to examine which proteins are targeted by the most promising drugs and if there are common trends among the targets, an approach designed by Clemens Hug, PhD, a research associate in the Laboratory of Systems Pharmacology and a co-first author.
The team applied the screening method to 80 FDA-approved and clinically tested drugs for a wide range of conditions. The analysis yielded a ranked list of candidates, with several anti-inflammatory drugs used to treat rheumatoid arthritis and blood cancers emerging as top contenders. These drugs belong to a class of medications known as Janus kinase inhibitors. The drugs work by blocking the action of inflammation-fueling Janus kinase proteins, suspected to play a role in Alzheimer’s disease and known for their role in autoimmune conditions. The team’s analyses also pointed to other potential treatment targets for further investigation.
“We are excited to share these results with the academic and pharmaceutical research communities. Our hope is that further validation by other researchers will refine the prioritization of these drugs for clinical investigation,” says Mark Albers, MD, PhD, the Frank Wilkins Jr. and Family Endowed Scholar and associate director of the Massachusetts Center for Alzheimer Therapeutic Science at MGH and a faculty member of the Laboratory of Systems Pharmacology at HMS. One of these drugs, baricitinib, will be investigated by Albers in a clinical trial for patients with subjective cognitive complaints, mild cognitive impairment, and Alzheimer’s disease that will be launching soon at MGH in Boston and at Holy Cross Health in Fort Lauderdale, Florida. “In addition, independent validation of the nominated drug targets could provide new insights into the mechanisms behind Alzheimer’s disease and lead to novel therapies,” says Albers.
Original Article: Artificial intelligence reveals current drugs that may help combat Alzheimer’s disease
More from: Massachusetts General Hospital
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Artificial intelligence to identify new drug treatments
- Exclusive: NHS to use AI to identify people at higher risk of hepatitis C
Screening programme will detect people with the deadly infection, which is often symptomless in early stages ...
- An Artificial Intelligence Predicted the Shape of Nearly Every Known Protein
Everyone knows the sci-fi movie cliche of an artificial intelligence program inevitably slipping down a villainous path. Thankfully, when ...
- Artificial Intelligence (AI) in Drug Discovery Market worth $4.0 billion by 2027 - Exclusive Report by MarketsandMarkets
The growth of this Artificial Intelligence ... Drug discovery is a very costly and lengthy process, owing to which there is a need for alternative tools for discovering new drugs.
- Artificial Intelligence (AI) in Drug Discovery Market worth $4.0 billion by 2027 - Exclusive Report by MarketsandMarkets™
The growth of this Artificial Intelligence in Drug Discovery Market is driven by the growing need to control drug discovery & development costs, and growing number of cross-industry collaborations and ...
- New MIT Computer Model Helps Identify Mutations That Drive Cancer
The system rapidly scans the genome of cancer cells and could help scientists find targets for new drugs. Cancer cells can have thousands of DNA mutations. However, only a small number of those ...
Go deeper with Google Headlines on:
Artificial intelligence to identify new drug treatments
Go deeper with Bing News on:
New Alzheimer’s treatment targets
- Is everything we think we know about Alzheimer's wrong?
If you've followed the news about Alzheimer's disease research in the past few months, you might find yourself wondering what else could go wrong.
- To Beat Alzheimer’s, Scientists Try New Ideas, Including Brain Mapping
Media outlets report on research into Alzheimer’s disease, including expanding fields of study and the potential for a diabetes drug to help protect against the illness. USA Today and The ...
- Have Scientists Been Wrong About Alzheimer’s for Decades?
A talk with Nobel laureate Thomas C. Südhof about a scandal rocking the world of Alzheimer’s research and how conceptions of the disease are changing.
- The Alzheimer’s Association recognizes seven researchers for contributions to the field of dementia science
The Alzheimer’s Association will present seven awards at the Alzheimer’s Association International Conference 2022, recognizing researchers for their varied expertise, noteworthy achievements and ...
- Cognito Therapeutics Announces Proprietary Gamma Sensory Stimulation for 6-Months Reduces White Matter Atrophy in Alzheimer’s Disease Patients
Pivotal trials will launch this year to support clinical efficacy of gamma sensory stimulation in Alzheimer’s Disease. Cognito Therapeutics, announced today that its proprietary gamma sensory ...
Go deeper with Google Headlines on:
New Alzheimer’s treatment targets








